ERBB2 and neoplasm: With the use of a state-arrival extended Markov proportional hazard (PH) model, a multivariate analysis indicated the presence of a HER2-positive tumor treated with trastuzumab (P = 0.001) and chemotherapy followed by surgical procedure (P < 0.001) as favorable predictors of survival.